Option chain shows key data for SciSparc's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for SciSparc.

SciSparc (NASDAQ:SPRC) Stock, Option Chain

SciSparc Ltd is a specialty clinical-stage pharmaceutical company. It is engaged in developing several immunotherapy products and it owns patents in the immunotherapy field. It is focused on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. The company has two reportable segments; development of drugs based on cannabinoid molecules to be approved by an official regulatory authority (the company's operation); and online sales of a various range of hemp-based products including hemp gummies, hemp oil capsules, hemp gel, hemp cream, detox pills, height pills, antibacterial creams, and anti-aging creams, among other beauty and hair treatment products that are all manufactured in the United States.

Movers_Stocks

ASAN

CRVO

CUTR

FWRG

GMHS

KUKE

LFMD

LZMH

NPWR

SNOA

SPRC

STSS

TNON

TSVT

VYNE

Why Paymentus Holdings Shares Are Trading Higher By Over 8%; Here Are 20 Stocks Moving Premarket

benzingaai2023_stock_market_charts_on_multiple_computer_scree_03ada781-be05-460b-a6af-38988bc7658b_1

News

Movers

CMND

SciSparc Ltd (NASDAQ:SPRC) shares are ripping higher Monday after the company announced that its collaboration with Clearmind Medicine Inc (NASDAQ:CMND) led to a patent application for psychedelic therapy targeting cocaine addiction.

SciSparc Shares Are Soaring Monday: What&#39;s Going On?

wall street ai16

Equities

Eurozone

Commodities

Intraday Update

Markets

Trading Ideas

AEON

BHAT

BLRX

FUBO

Nasdaq Surges Over 200 Points; BioLineRx Shares Plummet

SciSparc Ltd

Health Care

Legal

Press Releases

Clearmind Medicine Announces Publication of Patent for Binge Behavior Psychedelic Combination Treatment in Mexico

SciSparc-Clearmind Collaboration Leads to Publication of Patent for Binge Behaviour Combination Treatment in Mexico

SciSparc Secures Favorable Settlement in Lawsuit It Filed, Receiving Cash Compensation and a Full Release from All Commitments, Royalties, and Allegations Asserted Against It on Claimed Core Technology

N2OFF Signs Definitive Agreement to Acquire Next-Gen Computational Drug Discovery Company, Targeting Hard To Treat Cancers

SciSparc Extends $2 Million Loan to Support AutoMax's Growth Following AutoMax's Entry into Direct Import of JAC Electric Vehicles

Contracts

SciSparc Signs Definitive Agreement to Sell MitoCareX, Computational Drug Discovery Company Targeting Resistant Cancers

Clearmind Medicine Announces Publication of Patent for Cocaine Addiction Psychedelic Combination Treatment in South Korea

SciSparc-Clearmind Collaboration Leads to Publication of Patent Application for Cocaine Addiction Psychedelic Combination Treatment in South Korea

Bulls Turn to Pennies STSS, ADTX, CSDX, SPRC, CBDW, YGTFF During Market Uncertainty – Small-Cap Stocks Poised for Big Moves

SciSparc-Clearmind Collaboration Leads to Filing of International Patent Application for Novel Treatment of Anorexia, Bulimia and other Eating Disorders

Comments

SciSparc

SciSparc (SPRC) Options

No option chain data available. Please try again later

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell